SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Positive Phase 3 DAYBREAK results for Kodiaks wet-AMD candidates Zenkuda and tabirafusp-tedboth met primary endpoints versus aflibercept, with Zenkuda showing extended dosing durabilitysparked a sharp rally. Traders are split between bullish momentum and possible short-covering versus concerns about profit-taking, dilution, and the still-pending FDA review.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp, high-volume rally is driving attention, with traders citing IBM-related enterprise AI and digital-identity integrations and Hederas broader AI partnerships as possible catalysts. Others say the trigger is unclear and point to momentum, short covering, or rotation from QNT, while debating whether the breakout can hold.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are drawing attention after CEO CJ Desai stepped down to join Meta, with former CEO Dev Ittycheria named interim chief and company guidance reaffirmed. Traders are split: many view the selloff as an overreaction and a dip-buying opportunity, while others worry about the abrupt leadership change and uncertainty heading into the investor day.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants reported selection by The Clearing House for its on-chain money initiative, alongside discussion of live UK tokenized-deposit activity, is fueling a sharp rally as traders point to institutional adoption and limited token supply. Bullish excitement over potential demand is tempered by debate over whether the banking deals translate into meaningful QNT token use, as well as concerns about volatility and profit-taking.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that Trump may offer Iran sanctions relief in exchange for nuclear progressand speculation about an imminent announcementdrove sharp intraday swings in SPY. Traders debated whether the headlines signaled real progress or were unsubstantiated, while high Treasury yields and oil-related inflation concerns remained a bearish counterweight.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Ampriuss federal defense grant to convert a domestic EV-battery line for high-energy-density drone cells is the main catalyst. Traders see potential in expanded U.S. production and defense demand, but many were frustrated when an initial rally faded and questioned the near-term impact, since the project is years from completion and the grant is not a customer order.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp move toward the $9 area has fueled talk of short covering and a possible squeeze, though traders disagree on whether the price action is lasting or another brief swing. Speculation about upcoming ANKTIVA newsparticularly international expansion and the FDAs papillary bladder-cancer reviewis adding interest, but no new catalyst is confirmed in the discussion.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Traders are linking CLFs sharp selloff to the proposed Mesabi Metallics steel plant in Iowa, while questioning whether its financing, tax breaks and construction plans will materialize. Some see it as a competitive threat and a risk to Cleveland-Cliffs Minnesota leases; others doubt the projects viability and argue it could strengthen the case for a CLF-POSCO partnership.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is drawing attention after promising VK2735 weight-loss and maintenance data was followed by a large stock-and-convertible offering, which traders say erased momentum and raised concerns about dilution and managements timing. Bulls see the data and added funding as support for the obesity-drug pipeline, while bears point to the financing overhang and a potentially long wait for further catalysts; buyout talk remains speculative.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Upbeat wet-AMD pipeline updates from Kodiak and 4D Molecular Therapeutics have heightened competition concerns and coincided with OCULs sharp selloff. Traders are divided: some worry rivals raise the bar for AXPAXLI, while others argue its durability data and FDA-aligned filing path remain differentiators.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
